BioScience Trends. 2024;18(6):505-524. (DOI: 10.5582/bst.2024.01394)
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
Tang HW, Zhang WW, Cao JN, Cao YB, Bi XY, Zhao HT, Zhang Z, Liu Z, Wan T, Lang R, Sun WB, Du SD, Yang YP, Lu YY, Zeng DB, Wu JS, Duan BW, Lin DD, Li F, Meng QH, Zhou J, Xing BC, Tian XD, Zhu JY, Gao J, Hao CY, Wang ZQ, Duan F, Wang ZJ, Wang MQ, Liang B, Chen YW, Xu YZ, Li K, Li CG, Hu MG, Wang ZH, Cai SW, Ji WB, Xia NX, Zheng WH, Wang HG, Li G, Zhu ZM, Huang ZY, Zhang WG, Tao KS, Liang J, Zhang KM, Dai CL, Li JT, Qiu Q, Guo Y, Wu LQ, Ding WB, Zhu ZY, Gu WQ, Cao JY, Wang ZS, Tian LT, Ding HG, Li GM, Zeng YY, Wang K, Yang N, Jin HS, Chen YJ, Yang YM, Xiu DR, Yan ML, Wang XD, Han QL, Jiao SC, Tan G, Wang JZ, Liu LX, Song JH, Liao JJ, Zhao H, Li P, Song TQ, Wang ZB, Yuan J, Hu BY, Yuan YF, Zhang M, Sun SY, Zhang JL, Wang WT, Wen TF, Yang JY, Du XL, Peng T, Xia F, Liu ZJ, Niu WB, Liang P, Xu JM, Zhao X, Zhu M, Wang HZ, Kuang M, Shen SL, Cui X, Zhou JX, Liu R, Sun HC, Fan J, Chen XP, Zhou J, Cai JQ, Lu SC; Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, Liver Study Group of Surgery Committee of Beijing Medical Association, Editorial Board of the Chinese Journal of Hepatobiliary Surgery.
Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has proven highly efficacious in treating advanced HCC, significantly extending patients' survival and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy, patients can receive long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the Healthy China 2030 blueprint, the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focused on the latest progress since the release of the Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition) and resulted in a new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice, standardize medical care, and promote the development of the discipline.
Full Text: 
